CA2944103A1 - Sulfoximine substituted quinazolines for pharmaceutical compositions - Google Patents
Sulfoximine substituted quinazolines for pharmaceutical compositions Download PDFInfo
- Publication number
- CA2944103A1 CA2944103A1 CA2944103A CA2944103A CA2944103A1 CA 2944103 A1 CA2944103 A1 CA 2944103A1 CA 2944103 A CA2944103 A CA 2944103A CA 2944103 A CA2944103 A CA 2944103A CA 2944103 A1 CA2944103 A1 CA 2944103A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- alkyl
- compound
- heterocyclyl
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14167373.1 | 2014-05-07 | ||
| EP14167373 | 2014-05-07 | ||
| PCT/EP2015/059453 WO2015169677A1 (en) | 2014-05-07 | 2015-04-30 | Sulfoximine substituted quinazolines for pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2944103A1 true CA2944103A1 (en) | 2015-11-12 |
Family
ID=50639371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2944103A Pending CA2944103A1 (en) | 2014-05-07 | 2015-04-30 | Sulfoximine substituted quinazolines for pharmaceutical compositions |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10167296B2 (enExample) |
| EP (1) | EP3140300B1 (enExample) |
| JP (1) | JP6479854B2 (enExample) |
| AU (1) | AU2015257917C1 (enExample) |
| CA (1) | CA2944103A1 (enExample) |
| ES (1) | ES2749186T3 (enExample) |
| WO (1) | WO2015169677A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170066778A1 (en) * | 2015-09-04 | 2017-03-09 | Aunova Medchem LLC | Solubility for target compounds |
| CN109069865A (zh) * | 2016-03-31 | 2018-12-21 | 南澳大利亚卫生与医学研究所有限公司 | 抑制高脂肪饮食相关病症的方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19712960A1 (de) | 1997-03-27 | 1998-10-01 | Hoechst Ag | Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten |
| SE0102147D0 (sv) | 2001-06-18 | 2001-06-18 | Pharmacia Ab | New methods |
| DE10294485T5 (de) | 2001-10-29 | 2004-04-29 | DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung | Mit Mnk-Kinase homologe Proteine, die in die Regulation der Energiehomöostase und den Organellenmetabolismus involviert sind |
| GB0315587D0 (en) | 2003-07-03 | 2003-08-13 | Univ Dundee | Anti-inflammatory assay and compounds |
| CN1942442B (zh) | 2004-04-08 | 2012-10-31 | 美国陶氏益农公司 | 杀虫用n-取代亚磺酰亚胺 |
| EP1746099A1 (en) | 2004-12-23 | 2007-01-24 | DeveloGen Aktiengesellschaft | Mnk1 or Mnk2 inhibitors |
| EP1899353A1 (en) * | 2005-06-22 | 2008-03-19 | DeveloGen Aktiengesellschaft | Thienopyrimidines for pharmaceutical compositions |
| CN101454325A (zh) | 2006-03-09 | 2009-06-10 | 法马科皮亚公司 | 用于治疗代谢性疾病的8-杂芳基嘌呤mnk2抑制剂 |
| CN101466716A (zh) * | 2006-04-07 | 2009-06-24 | 德维洛根股份公司 | 用于药物组合物的具有mnkl/mnk2抑制活性的噻吩并嘧啶 |
| EP2044051B1 (en) | 2006-06-22 | 2010-01-27 | BIOVITRUM AB (publ) | Pyridine and pyrazine derivatives as mnk kinase inhibitors |
| EP1889847A1 (en) * | 2006-07-10 | 2008-02-20 | DeveloGen Aktiengesellschaft | Pyrrolopyrimidines for pharmaceutical compositions |
| CA2687611A1 (en) * | 2007-05-24 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Novel sulphoximine-substituted quinoline and quinazoline derivatives as kinase inhibitors |
| AU2009286734A1 (en) * | 2008-08-26 | 2010-03-04 | Boehringer Ingelheim International Gmbh | Thienopyrimidines for pharmaceutical compositions |
| TW201102391A (en) | 2009-03-31 | 2011-01-16 | Biogen Idec Inc | Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use |
| TW201111378A (en) | 2009-09-11 | 2011-04-01 | Bayer Schering Pharma Ag | Substituted (heteroarylmethyl) thiohydantoins |
| PH12012501693A1 (en) | 2010-02-26 | 2012-11-05 | Boehringer Ingelheim Int | 4 - [cycloalkyloxy (hetero) arylamino] thieno [2,3 - d] pyrimidines having mnkl/mnk2 inhibiting activity for pharmaceutical compositions |
| BR112012021453A2 (pt) | 2010-02-26 | 2017-02-21 | Boehringer Ingelheim Int | tienopirimidina, sua composição farmacêutica e seu uso |
| UY33241A (es) * | 2010-02-26 | 2011-09-30 | Boehringer Ingelheim Int | ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?. |
| US9170933B2 (en) * | 2010-06-28 | 2015-10-27 | International Business Machines Corporation | Wear-level of cells/pages/sub-pages/blocks of a memory |
| AR088082A1 (es) | 2011-10-13 | 2014-05-07 | Lilly Co Eli | Moduladores selectivos del receptor androgeno |
| ES2591129T3 (es) | 2012-05-21 | 2016-11-25 | Bayer Pharma Aktiengesellschaft | Tienopirimidinas |
| TW201412740A (zh) * | 2012-09-20 | 2014-04-01 | Bayer Pharma AG | 經取代之吡咯并嘧啶胺基苯并噻唑酮 |
| US20150252047A1 (en) * | 2012-09-26 | 2015-09-10 | Bayer Pharma Aktiengesellschaft | Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperproliferative diseases |
| ES2635262T3 (es) * | 2012-11-09 | 2017-10-03 | Evotec International Gmbh | Quinazolinas sustituidas con sulfoximina para composiciones farmacéuticas |
| JP2016506944A (ja) * | 2013-02-01 | 2016-03-07 | バイエル・ファルマ・アクティエンゲゼルシャフト | 置換ピラゾロピリミジニルアミノ−インダゾール |
| WO2014206922A1 (en) * | 2013-06-28 | 2014-12-31 | Boehringer Ingelheim International Gmbh | Sulfoximine substituted quinazolines and their use as mnk1 and/or mnk2 kinase inhibitors |
| AU2014359456B2 (en) * | 2013-12-04 | 2019-01-24 | Evotec International Gmbh | Sulfoximine substituted quinazolines for pharmaceutical compositions |
-
2015
- 2015-04-30 CA CA2944103A patent/CA2944103A1/en active Pending
- 2015-04-30 ES ES15720077T patent/ES2749186T3/es active Active
- 2015-04-30 AU AU2015257917A patent/AU2015257917C1/en not_active Ceased
- 2015-04-30 US US15/308,712 patent/US10167296B2/en active Active
- 2015-04-30 EP EP15720077.5A patent/EP3140300B1/en active Active
- 2015-04-30 JP JP2016566786A patent/JP6479854B2/ja not_active Expired - Fee Related
- 2015-04-30 WO PCT/EP2015/059453 patent/WO2015169677A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| ES2749186T3 (es) | 2020-03-19 |
| AU2015257917C1 (en) | 2019-03-14 |
| US10167296B2 (en) | 2019-01-01 |
| EP3140300B1 (en) | 2019-08-14 |
| US20170260195A1 (en) | 2017-09-14 |
| AU2015257917B2 (en) | 2017-08-17 |
| JP6479854B2 (ja) | 2019-03-06 |
| JP2017514867A (ja) | 2017-06-08 |
| WO2015169677A1 (en) | 2015-11-12 |
| EP3140300A1 (en) | 2017-03-15 |
| AU2015257917A1 (en) | 2016-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2914525C (en) | Sulfoximine substituted quinazolines for pharmaceutical compositions | |
| EP2917185B1 (en) | Sulfoximine substituted quinazolines for pharmaceutical compositions | |
| EP2539346B1 (en) | 4-[heterocycloalkyloxy(hetero)arylamino] thieno[2,3-d]pyrimidines having mnk1/ mnk2 inhibiting activity for pharmaceutical compositions | |
| EP2539344B1 (en) | Halogen or cyano substituted thieno[2,3-d]pyrimidines having mnk1/ mnk2 inhibiting activity for pharmaceutical compositions | |
| WO2015091156A1 (en) | Sulfoximine substituted pyrrolotriazines for pharmaceutical compositions | |
| EP3077383B1 (en) | Sulfoximine substituted quinazolines for pharmaceutical compositions | |
| AU2015257917C1 (en) | Sulfoximine substituted quinazolines for pharmaceutical compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200122 |
|
| EEER | Examination request |
Effective date: 20200122 |
|
| EEER | Examination request |
Effective date: 20200122 |
|
| EEER | Examination request |
Effective date: 20200122 |
|
| EEER | Examination request |
Effective date: 20200122 |
|
| EEER | Examination request |
Effective date: 20200122 |
|
| EEER | Examination request |
Effective date: 20200122 |
|
| EEER | Examination request |
Effective date: 20200122 |
|
| EEER | Examination request |
Effective date: 20200122 |
|
| EEER | Examination request |
Effective date: 20200122 |
|
| EEER | Examination request |
Effective date: 20200122 |
|
| EEER | Examination request |
Effective date: 20200122 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B302 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - CONDITIONS FOR GRANT DETERMINED NOT COMPLIANT Effective date: 20240808 |